3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Leukemia, Myeloid, Acute
12
Multiple Myeloma
9
Lymphoma
8
Breast Neoplasms
8
Lymphoma, Non-Hodgkin
7
Hodgkin Disease
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Neuroblastoma
6
Lymphoma, Large B-Cell, Diffuse
4
Central Nervous System Neoplasms
4
Burkitt Lymphoma
4
Sarcoma
3
Medulloblastoma
3
Leukemia
3
Brain Neoplasms
3
Anemia, Refractory, with Excess of Blasts
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Retinoblastoma
2
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Malignant mesenchymal tumor
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Follicular
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Interventions
Melphalan
8
Dexamethasone
7
Bortezomib
6
Filgrastim
4
Cyclophosphamide
3
liposomal amphotericin B
2
Early Intervention, Educational
2
Darbepoetin alfa
2
Clinical Protocols
2
Calcium Dobesilate
2
ferrous sulfate
1
ferric gluconate
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
birtamimab
1
auricularum
1
Sucrose
1
Stem Cell Transplantation
1
Specimen Handling
1
Pharmacogenomic Testing
1
Peripheral Blood Stem Cell Transplantation
1
Ondansetron
1
Morphine
1
Magnetic Resonance Spectroscopy
1
Ketamine
1
Hypericum extract LI 160
1
Granulocyte Colony-Stimulating Factor
1
Fentanyl
1
Epoetin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Immunoglobulin Light-chain Amyloidosis
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT02489500
2018-09-10
VelRand
Boston Medical Center
Phase 3
Terminated
3 enrolled
11 charts